Company / Return on Equity (ROE)
MAXCYTE, INC. Return on Equity (ROE) History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-26.0%
FY2025
5-year range
-26.0% / -7.3%
FY2021-FY2025
Trend
-59.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
MAXCYTE, INC. reports negative total equity of -26.0% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-26.0% in FY2025 with a 3-year CAGR of -16.7%.
Declined from -9.3% to -26.0% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -16.7pp
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, return on equity (roe) decreased 59.3% year-over-year.
- Peak return on equity (roe) was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.96 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -26.0% | -59.3% |
| FY2024 | -16.3% | -76.0% |
| FY2023 | -9.3% | +0.0% |
| FY2022 | -9.3% | -27.8% |
| FY2021 | -7.3% | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026